MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3849
Released On: 4/7/2016
Views: 4586
Released On: 3/31/2016
Views: 3575
Released On: 3/24/2016
Views: 2915
Released On: 3/17/2016
Views: 2474
Released On: 3/11/2016
Views: 2320
Released On: 3/4/2016
Views: 2612
Released On: 3/3/2016
Views: 2310
Released On: 2/23/2016
Views: 3663
Released On: 2/12/2016
Views: 2667
Released On: 2/10/2016
Views: 2381
Released On: 2/9/2016
Views: 2542
Released On: 1/20/2016
Views: 4321
Released On: 1/14/2016
Views: 4786
Released On: 1/5/2016
Views: 3017
Released On: 12/18/2015
Views: 9347
Released On: 12/9/2015
Views: 2780
Released On: 12/3/2015
Views: 3225